SPA Pricing Education, Analytics & Decision Making Tools Webinar Series

Tag: Drug Pricing

How Pharma Companies Game the System to Keep Drugs Expensive | Harvard Business Review

How Pharma Companies Game the System to Keep Drugs Expensive | Harvard Business Review

I help the University of Utah hospital system manage its drug budgets and medication use policies, and in 2015 I got sticker shock. Our annual inpatient pharmacy cost for a single drug skyrocketed from $300,000 to $1.9 million. That’s because the drug maker Valeant suddenly increased the price of isoproterenol from $440 to roughly $2,700 […]

MedPAC Recommends New Part B Pricing System | Medpage Today

MedPAC Recommends New Part B Pricing System | Medpage Today

WASHINGTON — The Medicare Payment Advisory Commission (MedPAC) voted unanimously Thursday to recommend a competitive pricing program and make other changes to reimbursement for drugs under Part B of the Medicare program. “Medicare, as a large third-party payer, always needs to take steps to make sure it’s paying the right amount,” said commission member Paul […]

To Improve Pharmaceutical Pricing, Reform PBMs And Fix Health Care’s Systemic Problems | Forbes

To Improve Pharmaceutical Pricing, Reform PBMs And Fix Health Care’s Systemic Problems | Forbes

As a consequence, PBMs’ earnings are enhanced when manufacturers charge high list prices, but then pay large rebates and discounts to lower the actual transaction prices, creating a strong financial incentive for PBMs to support the current opaque pricing system. Ultimately, the complicated pricing structure for pharmaceuticals is problematic and diminishes the beneficial role prices […]

How a $37,000-a-year medicine sets a good model for drug pricing | STAT

How a $37,000-a-year medicine sets a good model for drug pricing | STAT

He vowed to price the medicine “responsibly” and avoid the anger that high drug prices have stirred. “You’ll get to judge me and see how we do,” he told me. To his credit, Schleifer appears to have delivered. The drug, called Dupixent, has a list price of $37,000 a year. This isn’t cheap. But Regeneron […]

Connecting the dots | PMLiVE

Connecting the dots | PMLiVE

In this post-Brexit, post-Trump, populist environment, the view is that everything is interrelated. The world is getting smaller. Things that happen ‘here’ impact what happens ‘there’. Six degrees of separation. A massive game of dominoes. The Arab Spring shows us that change starts from the bottom up which triggers, perhaps, a smouldering discontent in the […]

The Hidden Monopolies That Raise Drug Prices | American Prospective

The Hidden Monopolies That Raise Drug Prices | American Prospective

Frankil’s troubles cannot be traced back to insurers or drug companies, the usual suspects that most people deem responsible for raising costs in the health-care system. He blames a collection of powerful corporations known as pharmacy benefit managers, or PBMs. If you have drug coverage as part of your health plan, you are likely to […]

A Patient’s Optimistic Call For Bipartisan Drug-Pricing Reform | Forbes

A Patient’s Optimistic Call For Bipartisan Drug-Pricing Reform | Forbes

With our nation’s fight over the Affordable Care Act in the rear-view mirror, it’s time for Donald Trump and Congress to focus on a genuinely bipartisan issue: drug prices. According to the Kaiser Family Foundation, 8 in 10 Americans want to allow the government to negotiate prices for people on Medicare. By the same margin, Americans want to […]

New budget test puts UK on front line in global drug price fight | Reuters

New budget test puts UK on front line in global drug price fight | Reuters

RESPONSIBLE PRICING Carole Longson, director of NICE’s center for health technology evaluation, says the onus is on drugmakers to price medicines responsibly. “Given the pace of technological innovation, the demands of people who need healthcare and the return on investments that shareholders wish for, the system is struggling,” she said. “We need to find ways […]

U.S. lawmakers seek pricing info on PTC Therapuetics’ Duchenne drug | WHTC

U.S. lawmakers seek pricing info on PTC Therapuetics’ Duchenne drug | WHTC

(Reuters) – Two U.S. lawmakers sent a letter on Wednesday to PTC Therapeutics Inc, seeking information about the drugmaker’s pricing strategy for its recently acquired muscle-wasting disorder drug. PTC said last week that it would buy Marathon Pharmaceuticals LLC’s recently approved Duchenne muscular dystrophy drug (DMD), Emflaza, and promised to re-examine the hefty U.S. price […]

The Public Discourse Around Pharma and Biotech Pricing and What the Industry Can Do | Klick Health

The Public Discourse Around Pharma and Biotech Pricing and What the Industry Can Do | Klick Health

The pharma and biotech industries continue to face the perception of unfair drug pricing. If left unchecked the result will be an irreversible vilification of pharma as a whole. What can we do to mitigate these perceptions, and convey actual benefits? The views expressed here are those of the author and not necessarily those of […]